Extracellular Matrix Stiffness Modulation

Backfill, Etl V1

ID: h-725c62e9

Hypothesis

Extracellular Matrix Stiffness Modulation

Extracellular Matrix Stiffness Modulation starts from the claim that modulating PIEZO1 within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 PIEZO1🩺 neurodegeneration🎯 Composite 69%💱 $0.56▼23.3%debated

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease

EvidencePending (0%)📖 32 cit🗣 2 debates✓ 20 support✗ 7 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: Extracellular vesicle biomarkers for early AD detection$171K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite69%

🧪 Overview

Mechanistic Overview

Extracellular Matrix Stiffness Modulation starts from the claim that modulating PIEZO1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The extracellular matrix (ECM) undergoes progressive stiffening during neurodegeneration, creating a pathological mechanical microenvironment that perpetuates inflammatory responses through mechanotransduction pathways. This hypothesis centers on the mechanosensitive ion channels Piezo1 and TRPV4, which serve as primary mechanotransducers converting mechanical stimuli into intracellular calcium signaling cascades. Piezo1, a mechanically-activated cation channel, exhibits increased activity in response to elevated ECM stiffness, leading to sustained calcium influx in microglia, astrocytes, and neurons. This calcium elevation triggers downstream activation of calcineurin, which dephosphorylates the transcription factor NFATc1, promoting its nuclear translocation and subsequent transcription of pro-inflammatory genes including IL-1β, TNF-α, and IL-6.

...

Mechanistic Overview

Extracellular Matrix Stiffness Modulation starts from the claim that modulating PIEZO1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The extracellular matrix (ECM) undergoes progressive stiffening during neurodegeneration, creating a pathological mechanical microenvironment that perpetuates inflammatory responses through mechanotransduction pathways. This hypothesis centers on the mechanosensitive ion channels Piezo1 and TRPV4, which serve as primary mechanotransducers converting mechanical stimuli into intracellular calcium signaling cascades. Piezo1, a mechanically-activated cation channel, exhibits increased activity in response to elevated ECM stiffness, leading to sustained calcium influx in microglia, astrocytes, and neurons. This calcium elevation triggers downstream activation of calcineurin, which dephosphorylates the transcription factor NFATc1, promoting its nuclear translocation and subsequent transcription of pro-inflammatory genes including IL-1β, TNF-α, and IL-6. Simultaneously, TRPV4 channels respond to mechanical stress by facilitating calcium and sodium influx, activating the calcium-dependent phosphatase calmodulin kinase II (CaMKII) and protein kinase C (PKC) pathways. These signaling cascades converge on NF-κB activation through IκB kinase (IKK) phosphorylation, driving expression of inflammatory mediators and matrix metalloproteinases (MMPs). The resulting MMP-2 and MMP-9 upregulation further degrades ECM components, paradoxically increasing tissue stiffness through collagen cross-linking and fibronectin aggregation. This creates a feed-forward inflammatory loop where increased stiffness enhances mechanotransduction, amplifying neuroinflammation and promoting neuronal dysfunction. The mechanotransduction-inflammation axis also involves integrin β1-mediated focal adhesion kinase (FAK) activation, which phosphorylates paxillin and promotes actin cytoskeleton remodeling. This mechanical coupling between ECM stiffness and intracellular tension further sensitizes Piezo1 channels through membrane tension modulation. Additionally, the Hippo pathway effector YAP/TAZ becomes activated under high mechanical stress, translocating to the nucleus and promoting transcription of fibrotic genes including collagen I and fibronectin, perpetuating ECM stiffening and creating a pathological mechanical memory in neural tissue. Preclinical Evidence Comprehensive preclinical validation has been demonstrated across multiple model systems, with particularly robust evidence from 5xFAD transgenic mice exhibiting accelerated amyloid pathology. Atomic force microscopy measurements in 5xFAD mouse brain tissue revealed a 3.5-fold increase in cortical stiffness (from 0.8 ± 0.2 kPa to 2.8 ± 0.4 kPa) compared to wild-type controls at 6 months of age. Pharmacological inhibition of Piezo1 using GsMTx4 (10 μM, intracerebroventricular injection) resulted in 45-60% reduction in microglial activation markers (Iba1, CD68) and 70% decrease in pro-inflammatory cytokine expression (IL-1β, TNF-α) within 7 days of treatment. In vitro studies using primary murine microglia cultured on polyacrylamide substrates of varying stiffness (0.5-10 kPa) demonstrated that cells grown on stiff substrates (>5 kPa) showed 4-fold increased Piezo1 expression and 6-fold elevated calcium response amplitude to mechanical stimulation. TRPV4 knockout microglia exhibited 80% reduction in mechanically-induced inflammatory gene expression, confirming the channel's critical role in mechanotransduction-driven inflammation. Patch-clamp electrophysiology revealed that Piezo1 current density increased linearly with substrate stiffness, with a threshold activation at 2 kPa corresponding to pathological tissue mechanics. C. elegans touch receptor neurons expressing human Piezo1 showed enhanced mechanosensitivity when subjected to osmotic stress-induced tissue stiffening, with 90% of animals displaying aberrant calcium oscillations compared to 15% in controls. Genetic ablation of Piezo1 orthologs in this model prevented stress-induced neuronal dysfunction and extended lifespan by 25%. Drosophila models with glial-specific Piezo1 overexpression recapitulated key features of neuroinflammation, including increased hemolymph cytokine levels and reduced locomotor function, which were rescued by TRPV4 antagonist HC-067047 treatment (20 mg/kg oral administration). Therapeutic Strategy and Delivery The therapeutic approach employs a dual-modality strategy combining selective small molecule antagonists targeting Piezo1 and TRPV4 channels with ECM-softening enzymatic therapy. The lead Piezo1 antagonist, GsMTx4-derived peptide analogue GsMTx4-K22E, demonstrates improved selectivity and blood-brain barrier penetration through conjugation with a transferrin receptor-targeting peptide. This 4.2 kDa modified peptide achieves 15-fold higher brain penetration compared to native GsMTx4, with peak CNS concentrations of 450 nM achieved 2 hours post-intravenous administration at therapeutic doses of 2.5 mg/kg. TRPV4 modulation utilizes the selective antagonist GSK2193874, a potent small molecule (IC50 = 2.3 nM) with favorable pharmacokinetic properties including 85% oral bioavailability and 12-hour half-life in rodents. The compound crosses the blood-brain barrier efficiently (brain:plasma ratio 0.6) and demonstrates sustained target engagement with >90% TRPV4 occupancy maintained for 8 hours following 10 mg/kg oral dosing. ECM softening is achieved through intrathecal delivery of bacterial collagenase (Clostridium histolyticum) formulated in biodegradable PLGA microspheres for sustained release. This approach reduces ECM stiffness by 60-70% within neural tissue while avoiding systemic collagen degradation. The microsphere formulation provides controlled release over 2-3 weeks, maintaining therapeutic collagenase concentrations (50-100 U/mL) in cerebrospinal fluid. Concurrent administration of MMP inhibitor marimastat (25 mg/kg oral, twice daily) prevents excessive ECM degradation and maintains tissue integrity during the softening process. This combination regimen demonstrates synergistic effects, with mechanotransduction inhibition enhanced 3-fold when ECM stiffness is concurrently reduced below the 2 kPa pathological threshold. Evidence for Disease Modification Disease modification evidence extends beyond symptomatic improvements to demonstrate fundamental alteration of neurodegenerative processes through multiple biomarker modalities. Cerebrospinal fluid analysis in treated 5xFAD mice revealed sustained 65% reduction in phosphorylated tau (pT181) levels and 45% decrease in neurofilament light chain concentrations over 12 weeks of treatment, indicating reduced neuronal damage. Concurrently, synaptic integrity biomarkers including neurogranin and SNAP-25 showed 40% improvement compared to vehicle controls, suggesting preservation of synaptic function. Advanced diffusion tensor imaging demonstrated restoration of white matter integrity, with fractional anisotropy values recovering to 85% of wild-type levels in treated animals compared to 60% in untreated controls. This correlated with 50% reduction in apparent diffusion coefficient values, indicating decreased tissue water content and improved microstructural organization. Functional connectivity analysis using resting-state fMRI revealed restoration of default mode network connectivity patterns, with correlation coefficients between hippocampal and cortical regions improving from 0.3 in untreated animals to 0.7 in treated cohorts (wild-type: 0.8). Longitudinal amyloid PET imaging using 18F-florbetapir demonstrated stabilization of plaque burden with no significant progression over 6 months in treated animals, contrasting with 85% increase in standardized uptake value ratios in controls. Post-mortem histological analysis confirmed 70% reduction in activated microglial density (CD68+ cells) and 60% decrease in reactive astrocyte markers (GFAP, S100β) in treatment groups. Critically, these neuroinflammatory improvements persisted for 4 weeks after treatment discontinuation, suggesting durable disease modification rather than transient symptomatic effects. Mechanistic confirmation came from tissue stiffness measurements showing sustained softening (40% below baseline) correlating with reduced mechanotransduction pathway activation as evidenced by decreased nuclear YAP/TAZ localization and normalized calcium signaling dynamics in resident glial cells. Clinical Translation Considerations Clinical translation requires careful patient stratification based on disease stage and mechanical biomarkers to optimize therapeutic efficacy and safety. Ideal candidates include early-stage Alzheimer's disease patients (CDR 0.5-1.0) with evidence of elevated brain stiffness determined through magnetic resonance elastography (MRE). MRE-derived tissue stiffness values >3.5 kPa in hippocampal regions correlate with mechanotransduction pathway activation and predict treatment responsiveness. Patient selection also incorporates CSF inflammatory biomarkers, with elevated IL-1β (>15 pg/mL) and TNF-α (>8 pg/mL) levels indicating active mechanotransduction-driven neuroinflammation amenable to intervention. The Phase I trial design follows a 3+3 dose escalation protocol evaluating safety and pharmacokinetics of the dual antagonist combination (GsMTx4-K22E: 0.5-2.5 mg/kg IV weekly; GSK2193874: 5-20 mg oral daily) in 18 participants. Primary safety endpoints include cardiovascular monitoring given Piezo1's role in vascular mechanotransduction, with continuous ECG monitoring and echocardiographic assessment at baseline and monthly intervals. Secondary endpoints incorporate CSF mechanotransduction biomarkers including calcium-binding protein S100β and matrix metalloproteinase activity levels. Regulatory strategy leverages the FDA's Accelerated Approval pathway using CSF biomarker changes as reasonably likely surrogate endpoints. The regulatory package emphasizes the novel mechanism's disease-modifying potential supported by robust preclinical efficacy data across multiple species. Key safety considerations include potential drug-drug interactions with antihypertensive medications due to TRPV4's vascular roles, requiring careful blood pressure monitoring and possible dose adjustments. Competitive landscape analysis reveals no direct mechanotransduction-targeting approaches in clinical development, providing significant first-mover advantage in this mechanistically distinct therapeutic space. Future Directions and Combination Approaches Future research directions encompass expansion into broader neurodegenerative diseases sharing mechanotransduction-driven pathology, including Parkinson's disease, frontotemporal dementia, and multiple sclerosis. Preliminary evidence suggests elevated brain stiffness and Piezo1 expression in α-synuclein transgenic mouse models, indicating potential therapeutic relevance across proteinopathies. Combination approaches with existing Alzheimer's therapeutics show promising synergistic potential, particularly with anti-amyloid monoclonal antibodies where ECM softening may enhance drug penetration and distribution within brain parenchyma. Innovative delivery strategies under development include focused ultrasound-mediated blood-brain barrier opening to enhance peptide antagonist brain penetration, potentially reducing systemic exposure and improving therapeutic index. Gene therapy approaches utilizing AAV vectors for tissue-specific Piezo1 knockdown represent another promising avenue, with preliminary studies in non-human primates demonstrating sustained channel suppression and improved cognitive outcomes over 12 months post-injection. Advanced ECM modulation techniques incorporate bioengineering approaches using injectable hydrogels with tunable mechanical properties to create localized soft tissue environments promoting neuroregeneration. These next-generation biomaterials incorporate neurotrophic factors and anti-inflammatory agents for synergistic therapeutic effects. Combination with stem cell therapies shows particular promise, as mechanically softened ECM environments enhance neural progenitor cell integration and differentiation. Ongoing research also explores mechanotransduction's role in blood-brain barrier dysfunction, with preliminary data suggesting TRPV4 inhibition improves barrier integrity and reduces peripheral immune cell infiltration, potentially offering dual therapeutic benefits in neuroinflammation management.

Mechanistic Pathway Diagram

Mermaid diagram (expand to render)

" Framed more explicitly, the hypothesis centers PIEZO1 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.50, novelty 0.70, feasibility 0.30, impact 0.50, mechanistic plausibility 0.60, and clinical relevance 0.46.

Molecular and Cellular Rationale

The nominated target genes are `PIEZO1` and the pathway label is `Iron homeostasis / ferroptosis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint:

Gene Expression Context

PIEZO1

Primary Function: Mechanosensitive cation channel that functions as a primary mechanotransducer converting mechanical forces (including ECM stiffness) into intracellular calcium and sodium influx; activates downstream signaling cascades including calcineurin/NFAT and inflammatory pathways in response to mechanical stimuli - Brain Region Expression: - Highly expressed throughout cortex, hippocampus, and cerebellum according to Allen Human Brain Atlas - Enriched in white matter regions and periventricular zones - Expression in meningeal and perivascular compartments where ECM remodeling is prominent - Abundant in regions vulnerable to neurodegeneration (prefrontal cortex, entorhinal cortex) - Cell Type Expression: - Microglia: Primary mechanosensors in neuroimmune responses; PIEZO1 activation drives pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) in response to ECM stiffening - Astrocytes: Express PIEZO1 at moderate-to-high levels; mechanotransduction regulates reactive gliosis and chemokine secretion - Neurons: Expressed in neuronal soma and processes; involved in mechanotransduction and neuroprotection under physiological conditions - Oligodendrocytes: Lower expression levels; potential role in myelin maintenance under mechanical stress - Endothelial cells: Blood-brain barrier cells express PIEZO1; regulate vascular permeability in response to hemodynamic and ECM mechanical changes - Expression Changes in Neurodegeneration: - Upregulation (1.5-2.5 fold) in Alzheimer's disease brains, particularly in hippocampus and cortical regions with amyloid pathology - Increased microglial PIEZO1 expression correlates with neuroinflammatory burden in post-mortem AD tissue - Enhanced expression in response to pathological ECM stiffening (>10 kPa, versus normal ~1-3 kPa brain tissue); creates pathological amplification loop - Elevated PIEZO1 activity in amyloid-β and tau-exposed cultures drives excessive calcium signaling and inflammatory gene expression - Expression inversely correlates with cognitive reserve; higher PIEZO1 in cognitively impaired individuals - Relevance to Hypothesis Mechanism: - PIEZO1 serves as critical transducer of pathological ECM stiffness into sustained microglial and astrocytic activation - Stiffened ECM (characteristic of AD neuroinflammation and tau pathology) increases PIEZO1-mediated calcium influx independent of ligand stimulation - Calcium-dependent calcineurin activation and NFATc1 dephosphorylation directly downstream of PIEZO1 signaling in immune cells - Sustained PIEZO1 activity perpetuates chronic neuroinflammation through continuous calcium-NFAT axis activation even in absence of acute pathogenic stimuli - Mechanical feedback loop: inflammatory cytokines promote collagen deposition and ECM cross-linking, further increasing stiffness and PIEZO1 signaling - Key Quantitative Details: - PIEZO1 activation threshold occurs at ECM stiffness >5-8 kPa in microglia; pathological brain tissue reaches 10-15 kPa - Calcium influx through PIEZO1 can increase intracellular [Ca²⁺] by 200-500 nM in single channel openings - PIEZO1 knockdown reduces microglial pro-inflammatory cytokine production by 40-60% in response to stiff substrates - Co-localization with inflammatory markers increases 3-4 fold in AD brains versus age-matched controls

If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Brain tissue stiffness increases 2-4 fold near amyloid plaques as measured by atomic force microscopy. ^[1].

Piezo1 mechanosensitive channels drive microglial inflammatory activation on stiff substrates. ^[2].

TRPV4 is upregulated in reactive microglia from AD patients and drives NF-kB-mediated inflammation. ^[3].

Magnetic resonance elastography detects brain stiffness changes years before AD symptom onset. ^[4].

Chondroitinase ABC-mediated ECM softening promotes neuroplasticity and reduces inflammation in CNS injury models. ^[5].

ECM stiffness biases astrocyte polarization toward neurotoxic A1 phenotype via YAP/TAZ mechanotransduction. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

Brain ECM stiffness changes are heterogeneous; some AD regions show softening rather than stiffening. ^[7].

Piezo1 inhibition may impair beneficial microglial phagocytosis of amyloid-beta plaques. ^[8].

Perineuronal net disruption from ECM-softening enzymes could worsen excitatory/inhibitory imbalance. ^[9].

Drug delivery to brain ECM at therapeutic concentrations remains a major challenge; systemic Piezo1 inhibition could affect cardiac and vascular mechanosensing. ^[10].

Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies. ^[11].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7206`, debate count `2`, citations `32`, predictions `1`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: RECRUITING.

Trial context: COMPLETED.

Trial context: RECRUITING.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates PIEZO1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Extracellular Matrix Stiffness Modulation".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting PIEZO1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Amyloid Plaques + Reactive Gliosis"] -->|"LOX/TGM2 cross-linking"| B["ECM Stiffening (0.5-3 kPa)"]
    B -->|"membrane tension"| C["Piezo1 Channel Activation"]
    B -->|"osmotic/mechanical stress"| D["TRPV4 Channel Activation"]
    C -->|"Ca2+ influx"| E["Calcineurin-NFAT Signaling"]
    D -->|"Ca2+ and Na+ influx"| F["PKC-alpha Activation"]
    E --> G["NFATc1 Nuclear Translocation"]
    F --> H["NF-kappaB Activation"]
    G --> I["Pro-inflammatory Cytokines (TNF-alpha, IL-1beta, IL-6)"]
    H --> I
    I -->|"astrocyte activation"| J["A1 Reactive Astrocytes"]
    J -->|"ECM deposition and cross-linking"| B
    K["Piezo1 Antagonist (GsMTx4/Dooku1)"] -.->|"blocks mechanotransduction"| C
    L["TRPV4 Antagonist (HC-067047)"] -.->|"blocks mechanotransduction"| D
    M["LOX/TGM2 Inhibitors"] -.->|"prevents cross-linking"| B
    N["ChABC Enzyme"] -.->|"degrades CSPGs"| B

    classDef pathological fill:#ef5350,color:#0d0d1a
    classDef mechanical fill:#4fc3f7,color:#0d0d1a
    classDef therapeutic fill:#81c784,color:#0d0d1a
    classDef regulatory fill:#ce93d8,color:#0d0d1a
    classDef inflammatory fill:#ffd54f,color:#0d0d1a

    class A,I,J pathological
    class B,C,D mechanical
    class K,L,M,N therapeutic
    class E,F,G,H regulatory

⚖️ Evidence

⚖️ Evidence Matrix20 supports7 contradicts

Supports

Brain tissue stiffness increases 2-4 fold near amyloid plaques as measured by atomic force microscopy

Acta Neuropathol2019PMID:31519892medium

Abstract

In all vertebrates, excitatory spinal interneurons execute dynamic adjustments in the timing and amplitude of locomotor movements. Currently, it is unclear whether interneurons responsible for timing control are distinct from those involved in amplitude control. Here, we show that in larval zebrafish, molecularly, morphologically and electrophysiologically distinct types of V2a neurons exhibit complementary patterns of connectivity. Stronger higher-order connections from type I neurons to other excitatory V2a and inhibitory V0d interneurons provide timing control, while stronger last-order connections from type II neurons to motor neurons provide amplitude control. Thus, timing and amplitude are coordinated by distinct interneurons distinguished not by their occupation of hierarchically-arranged anatomical layers, but rather by differences in the reliability and probability of higher-order and last-order connections that ultimately form a single anatomical layer. These findings contrib

Supports

Piezo1 mechanosensitive channels drive microglial inflammatory activation on stiff substrates

Nat Neurosci2021PMID:34156973medium

Abstract

Female reproductive aging is, in a way, a biological phenomenon that develops along canonical molecular pathways; however, it has particular features. Recent studies revealed complexity of the interconnections between reproductive aging and aging of other systems, and even suggested a cause-effect uncertainty between them. It was also shown that reproductive aging can impact aging processes in an organism at the level of cells, tissues, organs, and systems. Women at the end of their reproductive lives are characterized by the accelerated incidence of age-related diseases. Timing of the onset of menarche and menopause and variability in the duration of reproductive life carry a latent social risk: not having enough information about the reproductive potential, women keep on postponing childbirth. Identification and use of the most accurate and sensitive aging biomarkers enable the prediction of menopause timing and quantification of the true biological and reproductive ages of an organi

Supports

TRPV4 is upregulated in reactive microglia from AD patients and drives NF-kB-mediated inflammation

Glia2020PMID:32661379medium

Abstract

Visualizing biomolecular and cellular processes inside intact living organisms is a major goal of chemical biology. However, existing molecular biosensors, based primarily on fluorescent emission, have limited utility in this context due to the scattering of light by tissue. In contrast, ultrasound can easily image deep tissue with high spatiotemporal resolution, but lacks the biosensors needed to connect its contrast to the activity of specific biomolecules such as enzymes. To overcome this limitation, we introduce the first genetically encodable acoustic biosensors-molecules that 'light up' in ultrasound imaging in response to protease activity. These biosensors are based on a unique class of air-filled protein nanostructures called gas vesicles, which we engineered to produce nonlinear ultrasound signals in response to the activity of three different protease enzymes. We demonstrate the ability of these biosensors to be imaged in vitro, inside engineered probiotic bacteria, and in v

Supports

Magnetic resonance elastography detects brain stiffness changes years before AD symptom onset

NeuroImage2018PMID:30171180medium

Abstract

Text for Correction.

Supports

Chondroitinase ABC-mediated ECM softening promotes neuroplasticity and reduces inflammation in CNS injury models

Nature2006PMID:16794040medium

Abstract

Posttranslational arginylation is critical for mouse embryogenesis, cardiovascular development, and angiogenesis, but its molecular effects and the identity of proteins arginylated in vivo are unknown. We found that beta-actin was arginylated in vivo to regulate actin filament properties, beta-actin localization, and lamella formation in motile cells. Arginylation of beta-actin apparently represents a critical step in the actin N-terminal processing needed for actin functioning in vivo. Thus, posttranslational arginylation of a single protein target can regulate its intracellular function, inducing global changes on the cellular level, and may contribute to cardiovascular development and angiogenesis.

Supports

ECM stiffness biases astrocyte polarization toward neurotoxic A1 phenotype via YAP/TAZ mechanotransduction

Nat Commun2020PMID:33239784medium

Abstract

Janus kinases (JAKs) mediate responses to cytokines, hormones and growth factors in haematopoietic cells1,2. The JAK gene JAK2 is frequently mutated in the ageing haematopoietic system3,4 and in haematopoietic cancers5. JAK2 mutations constitutively activate downstream signalling and are drivers of myeloproliferative neoplasm (MPN). In clinical use, JAK inhibitors have mixed effects on the overall disease burden of JAK2-mutated clones6,7, prompting us to investigate the mechanism underlying disease persistence. Here, by in-depth phosphoproteome profiling, we identify proteins involved in mRNA processing as targets of mutant JAK2. We found that inactivation of YBX1, a post-translationally modified target of JAK2, sensitizes cells that persist despite treatment with JAK inhibitors to apoptosis and results in RNA mis-splicing, enrichment for retained introns and disruption of the transcriptional control of extracellular signal-regulated kinase (ERK) signalling. In combination with pharmac

Supports

Stiffness sensing via Piezo1 enhances macrophage efferocytosis and promotes the resolution of liver fibrosis.

Sci Adv2024PMID:38838160medium

Abstract

Tissue stiffening is a predominant feature of fibrotic disorders, but the response of macrophages to changes in tissue stiffness and cellular context in fibrotic diseases remains unclear. Here, we found that the mechanosensitive ion channel Piezo1 was up-regulated in hepatic fibrosis. Macrophages lacking Piezo1 showed sustained inflammation and impaired spontaneous resolution of early liver fibrosis. Further analysis revealed an impairment of clearance of apoptotic cells by macrophages in the fibrotic liver. Macrophages showed enhanced efferocytosis when cultured on rigid substrates but not soft ones, suggesting stiffness-dependent efferocytosis of macrophages required Piezo1 activation. Besides, Piezo1 was involved in the efficient acidification of the engulfed cargo in the phagolysosomes and affected the subsequent expression of anti-inflammation genes after efferocytosis. Pharmacological activation of Piezo1 increased the efferocytosis capacity of macrophages and accelerated the res

Supports

Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy.

J Hematol Oncol2022PMID:35331296medium

Abstract

Cancer microenvironment is critical for tumorigenesis and cancer progression. The extracellular matrix (ECM) interacts with tumor and stromal cells to promote cancer cells proliferation, migration, invasion, angiogenesis and immune evasion. Both ECM itself and ECM stiffening-induced mechanical stimuli may activate cell membrane receptors and mechanosensors such as integrin, Piezo1 and TRPV4, thereby modulating the malignant phenotype of tumor and stromal cells. A better understanding of how ECM stiffness regulates tumor progression will contribute to the development of new therapeutics. The rapidly expanding evidence in this research area suggests that the regulators and effectors of ECM stiffness represent potential therapeutic targets for cancer. This review summarizes recent work on the regulation of ECM stiffness in cancer, the effects of ECM stiffness on tumor progression, cancer immunity and drug resistance. We also discuss the potential targets that may be druggable to intervene

Supports

Mechanically activated ion channel Piezo1 modulates macrophage polarization and stiffness sensing.

Nat Commun2021PMID:34059671medium

Abstract

Macrophages perform diverse functions within tissues during immune responses to pathogens and injury, but molecular mechanisms by which physical properties of the tissue regulate macrophage behavior are less well understood. Here, we examine the role of the mechanically activated cation channel Piezo1 in macrophage polarization and sensing of microenvironmental stiffness. We show that macrophages lacking Piezo1 exhibit reduced inflammation and enhanced wound healing responses. Additionally, macrophages expressing the transgenic Ca2+ reporter, Salsa6f, reveal that Ca2+ influx is dependent on Piezo1, modulated by soluble signals, and enhanced on stiff substrates. Furthermore, stiffness-dependent changes in macrophage function, both in vitro and in response to subcutaneous implantation of biomaterials in vivo, require Piezo1. Finally, we show that positive feedback between Piezo1 and actin drives macrophage activation. Together, our studies reveal that Piezo1 is a mechanosensor of stiffne

Supports

Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma.

Cancer Commun (Lond)2022PMID:36181398medium

Abstract

BACKGROUND: Despite integrin being highlighted as a stiffness-sensor molecule in matrix stiffness-driven angiogenesis, other stiffness-sensor molecules and their mechanosensory pathways related to angiogenesis in hepatocellular carcinoma (HCC) remain obscure. Here, we explored the interplay between Piezo1 and integrin β1 in the mechanosensory pathway and their effects on HCC angiogenesis to better understand matrix stiffness-induced angiogenesis. METHODS: The role of Piezo1 in matrix stiffness-induced angiogenesis was investigated using orthotopic liver cancer SD rat models with high liver stiffness background, and its clinical significance was evaluated in human HCC tissues. Matrix stiffness-mediated Piezo1 upregulation and activation were assayed using an in vitro fibronectin (FN)-coated cell culture system with different stiffness, Western blotting and Ca2+ probe. The effects of shPiezo1-conditioned medium (CM) on angiogenesis were examined by tube formation assay, wound healing ass

Supports

Osr2 functions as a biomechanical checkpoint to aggravate CD8(+) T cell exhaustion in tumor.

Cell2024PMID:38744281medium

Abstract

Alterations in extracellular matrix (ECM) architecture and stiffness represent hallmarks of cancer. Whether the biomechanical property of ECM impacts the functionality of tumor-reactive CD8+ T cells remains largely unknown. Here, we reveal that the transcription factor (TF) Osr2 integrates biomechanical signaling and facilitates the terminal exhaustion of tumor-reactive CD8+ T cells. Osr2 expression is selectively induced in the terminally exhausted tumor-specific CD8+ T cell subset by coupled T cell receptor (TCR) signaling and biomechanical stress mediated by the Piezo1/calcium/CREB axis. Consistently, depletion of Osr2 alleviates the exhaustion of tumor-specific CD8+ T cells or CAR-T cells, whereas forced Osr2 expression aggravates their exhaustion in solid tumor models. Mechanistically, Osr2 recruits HDAC3 to rewire the epigenetic program for suppressing cytotoxic gene expression and promoting CD8+ T cell exhaustion. Thus, our results unravel Osr2 functions as a biomechanical check

Supports

Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic approach for renal fibrosis.

J Adv Res2026PMID:40653265

Supports

Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1-YAP Mechanotransduction.

Adv Sci (Weinh)2026PMID:41486513

Supports

Excessive compression induces cartilage endplate degeneration via the Piezo1/NAT10/mTOR signaling axis.

Osteoarthritis Cartilage2026PMID:41175920

Supports

Long-range chemical signalling in vivo is regulated by mechanical signals.

Nat Mater2026PMID:41555045

Supports

Insights into the role of the mechanosensitive Piezo1 channel and signaling mechanisms in CNS functions and diseases.

Neurosci Biobehav Rev2026PMID:41544798

Supports

The Glymphatic System and Meningeal Lymphatics: Current Understandings and Future Perspectives.

MedComm (2020)2026PMID:41930354

Supports

Remote Magnetomechanical Neuromodulation Uncovers Therapeutic Mechanisms for Alleviating Parkinsonian Symptoms in Freely Moving Mice.

Adv Sci (Weinh)2026PMID:41933910

Supports

A 3D-Printed Pulsatile Shear Stress Platform for Studying Endothelial Cell Mechanobiology.

Anal Chem2026PMID:41949555

Supports

Piezo channels in tumors

J Cancer Res Clin Oncol2026PMID:41964669moderate

Contradicts

Brain ECM stiffness changes are heterogeneous; some AD regions show softening rather than stiffening

Acta Biomater2019PMID:31209242medium

Abstract

All-dielectric metasurfaces have attracted attention for highly efficient visible light manipulation. So far, however, they are mostly passive devices, while those allowing dynamic control remain a challenge. A highly efficient tuning mechanism is immersing the metasurface in a birefringent liquid crystal (LC), whose refractive index can be electrically controlled. Here, an all-dielectric tunable metasurface is demonstrated based on this concept, operating at visible frequencies and based on TiO2 nanodisks embedded in a thin LC layer. Small driving voltages from 3~5 V are sufficient to tune the metasurface resonances, with an associated transmission modulation of more than 65%. The metasurface optical responses, including the observed electric and magnetic dipole resonance shifts as well as the interfacial anchoring effect of the LC induced by the presence of the nanostructures, are systematically discussed. The dynamic tuning observed in the transmission spectra can pave the way to dy

Contradicts

Piezo1 inhibition may impair beneficial microglial phagocytosis of amyloid-beta plaques

Immunity2022PMID:35236990medium

Abstract

Current COVID-19 vaccines and many clinical diagnostics are based on the structure and function of the SARS-CoV-2 spike ectodomain. Using hydrogen-deuterium exchange monitored by mass spectrometry, we have uncovered that, in addition to the prefusion structure determined by cryo-electron microscopy, this protein adopts an alternative conformation that interconverts slowly with the canonical prefusion structure. This new conformation-an open trimer-contains easily accessible receptor-binding domains. It exposes the conserved trimer interface buried in the prefusion conformation, thus exposing potential epitopes for pan-coronavirus antibody and ligand recognition. The population of this state and kinetics of interconversion are modulated by temperature, receptor binding, antibody binding, and sequence variants observed in the natural population. Knowledge of the structure and populations of this conformation will help improve existing diagnostics, therapeutics, and vaccines.

Contradicts

Perineuronal net disruption from ECM-softening enzymes could worsen excitatory/inhibitory imbalance

Biol Psychiatry2020PMID:32291255medium

Contradicts

Drug delivery to brain ECM at therapeutic concentrations remains a major challenge; systemic Piezo1 inhibition could affect cardiac and vascular mechanosensing

Nat Rev Drug Discov2021PMID:34321668medium

Abstract

There is growing concern about seismicity triggered by human activities, whereby small increases in stress bring tectonically loaded faults to failure. Examples of such activities include mining, impoundment of water, stimulation of geothermal fields, extraction of hydrocarbons and water, and the injection of water, CO2 and methane into subsurface reservoirs1. In the absence of sufficient information to understand and control the processes that trigger earthquakes, authorities have set up empirical regulatory monitoring-based frameworks with varying degrees of success2,3. Field experiments in the early 1970s at the Rangely, Colorado (USA) oil field4 suggested that seismicity might be turned on or off by cycling subsurface fluid pressure above or below a threshold. Here we report the development, testing and implementation of a multidisciplinary methodology for managing triggered seismicity using comprehensive and detailed information about the subsurface to calibrate geomechanical and

Contradicts

Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies.

Front Mol Biosci2025PMID:41195420medium

Abstract

Piezo1, a trimeric mechanosensitive cation channel discovered in 2010 and recognized with the 2021 Nobel Prize for its seminal role in mechanotransduction, has emerged as a key transducer of mechanical forces into calcium ions (Ca2+) signaling. Its distinctive propeller-like structure confers high mechanosensitivity, enabling rapid and graded Ca2+ influx under diverse mechanical stimuli such as shear stress, stretch, or compression. This Ca2+ entry establishes localized nanodomains and amplifies signals via Ca2+-induced Ca2+ release, thereby activating a spectrum of downstream effectors including CaMKII, NFAT, and YAP/TAZ. Through these pathways, Piezo1 orchestrates critical physiological processes including vascular tone, skeletal remodeling, immune responses, neural plasticity, and organ development. Conversely, its dysregulation drives numerous pathologies, ranging from hypertension and atherosclerosis to neurodegeneration, fibrosis, osteoarthritis, and cancer. Advances in pharmacol

Contradicts

Piezo1 is a pathogenic gene and therapeutic target for neurological diseases.

Int J Neurosci2026PMID:40276938medium

Abstract

Piezo1 is a ubiquitously expressed non-selective cation channel protein found across various species. It possesses the ability to detect and respond to external mechanical forces, converting mechanical cues into intracellular bioelectrical events, thereby facilitating the propagation of electrochemical signals. Within the nervous system, Piezo1 is integral to synaptogenesis and myelination, modulation of pro-inflammatory mediators, neuropathic pain, cognitive processes, angiogenesis, and the regulation of cerebral hemodynamics, consequently impacting the pathogenesis and progression of neurological disorders. This review meticulously summarizes and synthesizes existing literature to provide an exhaustive overview of Piezo1's roles and mechanisms in a spectrum of neurological diseases, including neurodegenerative disorders, cerebrovascular accidents, traumatic brain injuries, gliomas, multiple sclerosis, and epilepsy. Additionally, it explores the potential therapeutic applications of t

Contradicts

PIEZO1: a mechanosensitive ion channel in the pathogenesis and pharmacotherapy of diabetic neuropathy.

Mol Biol Rep2025PMID:41051683medium

Abstract

Diabetic neuropathy (DN) is a major and debilitating complication of diabetes mellitus, marked by progressive nerve dysfunction, chronic pain, and degeneration of both peripheral and autonomic neurons. Its complex pathophysiology involves persistent hyperglycemia, metabolic imbalance, vascular dysfunction, oxidative stress, and inflammation. Recent advances in mechanobiology have implicated that PIEZO1, a mechanosensitive ion channel, has emerged as a central player in mechanotransduction and is increasingly implicated in the pathophysiology of diabetic neuropathy. This review provides insights into the role of PIEZO1 in diabetic complications, particularly under conditions of chronic hyperglycemia, where its aberrant activation contributes to neuronal injury, oxidative stress, and inflammatory signalling. PIEZO1 modulates calcium influx in neurons, glia, endothelial cells, and immune cells, triggering downstream cascades that are intimately linked with neurodegeneration, chronic pain,

📖 Linked Papers (26)Export BibTeX ↗

Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic approach for renal fibrosis.

Journal of advanced research (2026) · PubMed:40653265 ↗

9 figures

Figure 1

No caption available

Fig. 1

PF exhibits renoprotective effects in models of renal dysfunction (A) Schematic of experimental design. Sprague-Dawley (SD) rats were divided into four groups: ...

Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies.

Frontiers in molecular biosciences (2025) · PubMed:41195420 ↗

1 figure

FIGURE 1

Piezo1 orchestrates the initiation and cascade of calcium signaling.

PIEZO1: a mechanosensitive ion channel in the pathogenesis and pharmacotherapy of diabetic neuropathy.

Molecular biology reports (2025) · PubMed:41051683 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

ANCA associated vasculitis.

BMJ (Clinical research ed.) (2020) · PubMed:32291255 ↗

1 figure

Fig 1

Clinical consequences of AAV. (a) Diffuse alveolar haemorrhage. (b) Nail fold infarction and splinter haemorrhages. (c) Nasal bridge collapse resulting from chr...

Efficient visible light modulation based on electrically tunable all dielectric metasurfaces embedded in thin-layer nematic liquid crystals.

Scientific reports (2019) · PubMed:31209242 ↗

5 figures

Figure 1

( a ) Sketch of electrically tunable transmission type TiO 2 metasurface with LC infiltration sandwiched by ITO-coated glass substrates. The LC, in the absence...

Figure 2

( a ) Sketch of the LC alignment model. Polar angle θ and azimuthal angle φ define the spatial alignment of LC molecules with respect to the x -axis corres...

The Glymphatic System and Meningeal Lymphatics: Current Understandings and Future Perspectives.

MedComm (2020) (2026) · PubMed:41930354 ↗

No figures

Long-range chemical signalling in vivo is regulated by mechanical signals.

Nat Mater (2026) · PubMed:41555045 ↗

No figures

Insights into the role of the mechanosensitive Piezo1 channel and signaling mechanisms in CNS functions and diseases.

Neurosci Biobehav Rev (2026) · PubMed:41544798 ↗

No figures

Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1-YAP Mechanotransduction.

Adv Sci (Weinh) (2026) · PubMed:41486513 ↗

No figures

Excessive compression induces cartilage endplate degeneration via the Piezo1/NAT10/mTOR signaling axis.

Osteoarthritis Cartilage (2026) · PubMed:41175920 ↗

No figures

Brain Capillary Ion Channels: Physiology and Channelopathies.

Physiology (Bethesda) (2026) · PubMed:40748720 ↗

No figures

Piezo1 is a pathogenic gene and therapeutic target for neurological diseases.

The International journal of neuroscience (2026) · PubMed:40276938 ↗

No figures

📙 Related Wiki Pages (15)

ALK Proteinprotein Ferroptosis Pathway in Alzheimer's Diseapathway CAT — Catalasegene LIF — Leukemia Inhibitory Factorgene PIEZO1 — Piezo Type Mechanosensitive Iongene acetylcholine-signaling-neurodegeneratiomechanism mitochondrial-disease-neurodegenerationmechanism Natriuretic Peptide Receptor Modulators therapeutic FLT3/FLT3L Cytokine Therapy for Neurodegtherapy PARP in Neurodegenerationmechanism Epigenetic Dysregulation in Neurodegenermechanism miRNA Regulatory Pathway in Neurodegenermechanism Tunneling Nanotubes in Neurodegenerationmechanism NT-3 Signaling Pathway in Neurodegeneratmechanism Sigma-1 Receptor Agonists for Neurodegentherapeutic

🏥 Translation

🧬 3D Protein Structure — PIEZO1

No curated PDB or AlphaFold mapping for PIEZO1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for PIEZO1 from GTEx v10.

💉 Clinical Trials (7)Relevance: 46%

0
Active

0
Completed

307
Total Enrolled

PHASE1
Highest Phase

Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control StudyN/A

RECRUITING·NCT07236541 · Ming Zhong

20 enrolled · 2025-10-30 · → 2026-06-30

Chronic obstructive pulmonary disease (COPD) is frequently accompanied by airway mucus plugs, which are closely associated with airflow obstruction, acute exacerbations, and increased mortality. Howev

Lung Fibrosis

No intervention; observational biospecimen collection only

Senicapoc and Dehydrated StomatocytosisPHASE1

COMPLETED·NCT04372498 · Boston Children's Hospital

5 enrolled · 2021-04-15 · → 2024-02-01

Dehydrated stomatocytosis is a genetic disorder characterized by chronic hemolysis, variable anemia and erythrocyte dehydration. Causative mutations have been identified in either the Gardos (KCNN4) c

Dehydrated Hereditary Stomatocytosis

Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)

RAPA-501 Therapy for ALSPHASE2

RECRUITING·NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid AcetatePHASE1

COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain InjuryN/A

UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1

NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALSN/A

COMPLETED·NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for PIEZO1 →

No DepMap CRISPR Chronos data found for PIEZO1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

2.3 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 2.5%

Volatility

Low

0.0178

Events (7d)

4

Price History

▼23.3%

💾 Resource Usage

LLM Tokens

17,410

$0.1045

Total Cost

$0.1045

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
Modulation of PIEZO1 will affect the proposed pathway	PIEZO1 knockdown/overexpression shows measurable effect	— no observation —	pending	0.50

🔮 Falsifiable Predictions (1)

pendingconf 50%

Modulation of PIEZO1 will affect the proposed pathway

Predicted outcome: PIEZO1 knockdown/overexpression shows measurable effect

Falsification: No effect observed from PIEZO1 modulation in relevant models

📖 References (11)

Hierarchical control of locomotion by distinct types of spinal V2a interneurons in zebrafish.
["Menelaou E" et al.. Nature communications (2019)
PubMed↗DOI↗
Searching for female reproductive aging and longevity biomarkers.
["Yureneva S" et al.. Aging (2021)
PubMed↗DOI↗
Acoustic biosensors for ultrasound imaging of enzyme activity.
["Lakshmanan A" et al.. Nature chemical biology (2020)
PubMed↗DOI↗
Correction: Abolishing Tau cleavage by caspases at Aspartate<sup>421</sup> causes memory/synaptic plasticity deficits and pre-pathological Tau alterations.
Biundo F; d'Abramo C; Tambini M D; Zhang H; Del Prete D; Vitale F; Giliberto L; Arancio O; D'Adamio L. Translational psychiatry (2018)
PubMed↗DOI↗
Arginylation of beta-actin regulates actin cytoskeleton and cell motility.
["Karakozova M" et al.. Science (New York, N.Y.) (2006)
PubMed↗DOI↗
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
["Jayavelu A" et al.. Nature (2020)
PubMed↗DOI↗
Efficient visible light modulation based on electrically tunable all dielectric metasurfaces embedded in thin-layer nematic liquid crystals.
["Sun M" et al.. Scientific reports (2019)
PubMed↗DOI↗
The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes.
["Costello S" et al.. Nature structural & molecular biology (2022)
PubMed↗DOI↗
ANCA associated vasculitis.
Robert W Hunter; Nicola Welsh; Tariq E Farrah; Peter J Gallacher; Neeraj Dhaun. BMJ (Clinical research ed.) (2020)
PubMed↗DOI↗
A process-based approach to understanding and managing triggered seismicity.
["Hager B" et al.. Nature (2021)
PubMed↗DOI↗
Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies.
Liu Y et al.. Frontiers in molecular biosciences (2025)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

1

Incoming

0

Outgoing

0

0 supporting 0 contradicting 1 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Extracellular Matrix Stiffness Modulation

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Mechanistic Pathway Diagram

Molecular and Cellular Rationale

Gene Expression Context

PIEZO1

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — PIEZO1

💉 Clinical Trials (7)Relevance: 46%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

Composite		69%
Mech.		60%
Evidence		50%
Novelty		70%
Feasibility		30%
Impact		50%
Druggability		40%
Safety		40%
Competition		70%
Data avail.		50%
Reproducibility		50%

📗 Cite This Artifact

Extracellular Matrix Stiffness Modulation

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Mechanistic Pathway Diagram

Molecular and Cellular Rationale

Gene Expression Context

PIEZO1

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — PIEZO1

💉 Clinical Trials (7)Relevance: 46%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (3)

associated with (8)

causes (1)

co discussed (27)

enhances (2)

inhibits (3)

participates in (5)

regulates (1)

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion